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http://dx.doi.org/10.1016/j.jfma.201Renal fibrosis is a disease affecting millions worldwide and is a harbinger of progressive renal
failure. Understanding the mechanisms of renal fibrosis is important for discovering new ther-
apies that are required to prevent loss of renal function. Recently, we identified pericytes that
line the kidney microvasculature as the precursor cells of the scar-producing myofibroblasts
during kidney injury. Kidney pericytes are extensively branched cells embedded within the
capillary basement membrane and stabilize the capillary network through tissue inhibitor of
metalloproteinase 3 and angiogenic growth factors. Pericytes detach from endothelial cells
and migrate into the interstitial space where they undergo a transition into myofibroblasts
after injury. Activation of endothelium, pericyteemyofibroblast transition, and recruitment
of inflammatory macrophages lead to capillary rarefaction and fibrosis. Targeting endothe-
liumepericyte crosstalk by inhibiting vascular endothelial cell growth factor receptors and
platelet-derived growth factor receptors in response to injury have been identified as new
therapeutic interventions. Furthermore, targeting macrophage activation has also been proven
as a novel and safe therapeutic approach for pericyteemyofibroblast transition. However, we
are still far from understanding the interaction between pericytes and other cellular elements
in normal physiology and during kidney fibrosis. Further studies will be required to translate
into more specific therapeutic approaches.
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Renal fibrosis is the final common pathway of a wide variety
of chronic kidney diseases (CKDs). Similar to wound healing,
renal fibrosis initiates a probably beneficial response when
the kidney is injured.1 However, persistent or repeated
injuries are believed to lead fibrosis to a maladaptive repair
process characterized by glomerulosclerosis, tubular
atrophy, interstitial fibrosis, and capillary rarefaction.2e5
Macrophages and myofibroblasts are at the heart of this
fibrotic process.6e10 Injuries and chronic inflammation
promote the expression of growth factors, cytokines, and
enzymes that are involved in the death of parenchymal
cells, and on the contrary, cell number expansion of
macrophages and myofibroblasts.2e4,6,8,9,11 a-Smooth
muscle actin (SMA) has been widely used as a robust marker
of myofibroblasts in the kidney, because collagen-
producing cells in culture induce production of this cyto-
skeletal protein. The transcription factor S100A4, also
known as fibroblast specific protein-1, encoded by gene
mts1 (for metastasis1) has been used as a marker of fibro-
blasts, but this marker has been shown to identify macro-
phages in the kidney and elsewhere.12e18 Myofibroblasts
synthesize and deposit components of pathological collag-
enous matrix that become scar tissue, leading to progres-
sive loss and contraction of normal kidney architecture, and
finally renal atrophy.11 Progressive renal fibrosis is accom-
panied with loss of renal function so that dialysis or renal
transplantation is required in patients with uremia. Devel-
opment of new therapies to treat progressive kidney
diseases has been held back by limited understanding of the
mechanisms by which disease progression occurs. Although
renal fibrosis has been questioned secondary to nephron
dysfunction rather than intrinsic to the kidney disease
progression, an increasing number of studies are pointing to
the final common pathway as central to dysfunction and
attrition of the nephron.6,19 Thus, effective treatments
targeting renal fibrosis to halt nephron demise or perhaps
improve renal function have the potential to provide great
medical and socioeconomical benefit.19 This review focuses
on the novel insights into pericyteemyofibroblast transition
and provides therapeutic targets in renal fibrosis.
Origin of myofibroblasts in renal fibrosis
It is widely accepted that in the injured kidney interstitial
myofibroblasts are the cells that generate collagenous
matrix, which if not resorbed, leads to scarring and organ
failure.20 Unlike skin, there have been no known resident
progenitor cells of myofibroblasts in the kidney until our
recent studies, however, many cell types in the kidney can
dedifferentiate into myofibroblasts in vitro, and take on
functional characteristics of myofibroblasts, including
generation of collagenous matrix and contraction of
matrix.21e23 The first possibility as previously reported is
that myofibroblasts in the kidney derive from epithelial
cells through the mechanism of epithelialemesenchymal
transition (EMT).24,25 It has been proposed, in a profibrotic
model in the kidney of unilateral ureteral obstruction
(UUO), that 30% of myofibroblasts derive from circulating
cells and the remainder derive from EMT of injured tubularepithelial cells.24 This study relied on the expression of
S100A4 (also called as fibroblast specific protein-1) to
identify fibroblasts in the kidney. However, studies by the
authors and others have recognized that S100A4 actually
identifies macrophages in the kidney and elsewhere.12e18
Although conditional ablation of S100A4þ cells has been
shown to abate kidney fibrosis,26 this antifibrotic effect
may result from the ablation of macrophages whose profi-
brotic role has been well studied.8,9,27 Lineage tracing
studies by us and others have not confirmed that injured
epithelial cells leave the confines of the tubular basement
membrane.28,29 In our work, we used transgenic mice with
promoter Six2-driven Cre recombinase to breed with CAG-
Bgeo,-DsRed.MST (Z/Red) mice that have LoxP-flanked
LacZ gene before DsRed gene.28 These Six2GCþ;Z/Redþ
bigenic offspring had permanent red fluorescence in their
tubular epithelial cells. UUO resulted in interstitial fibrosis
and marked expansion of interstitial aSMAþ myofibroblasts,
however, we did not identify a single interstitial cell with
red fluorescence. Many interstitial cells with S100A4 were
identified and they coexpressed markers of macrophages,
but none of the S100A4þ cells expressed red fluorescence.
In contrast, cultured proximal tubular epithelial cells could
be induced to express aSMA and S100A4 after transforming
growth factor (TGF)b1 stimulation. One elegant study by
Koesters et al has recently demonstrated that transgenic
overexpression of TGFb in kidney epithelial cells is suffi-
cient to trigger interstitial kidney fibrosis in the absence of
EMT.29 Bielesz et al also have shown no EMT in mice with
folic acid nephropathy.30 Therefore EMT of tubular
epithelial cells is not possible in injured kidneys.
The second possibility of the myofibroblast origin is
supposed to be from bone marrow, but its contribution has
remained unclear in the kidney.31e34 Studies that have used
aSMA as a marker of myofibroblasts and have reported the
contribution of bone marrow cells to the aSMAþ cells in the
injured kidney have yielded widely varying results.31e34
This variability may reflect some of the technical difficul-
ties with the assays used, including determining low-level
expression of aSMA and nonspecific binding resulting from
using mouse antibodies on mouse tissues.25 Elsewhere (in
other organ systems), similar problems have resulted in
uncertainty as to the proportion of myofibroblasts (if any)
that derive from circulating cells.33,35 Recent studies, using
lacZ-based reporters, have suggested that no myofibro-
blasts in the fibrotic kidney derive from circulating cells,32
but using LacZ as a marker in the kidney has been fraught
with problems due to low level enzyme expression and
high-level endogenous b galactosidase expression in the
kidney.34,36 The precise correlation of aSMA with patho-
logical collagen matrix producing cells in vivo has not been
determined, and aSMA is a surrogate marker (i.e., indirect)
for the cells that produce pathological collagenous matrix,
therefore, we need a marker of cells that are producing the
pathological matrix. Hence, we used such a robust marker
that expresses green fluorescence protein (GFP) under
control of the 3.2-kb collagen 1 (a1) promoter in transgenic
mice (Coll-GFP mice) whose collagen-producing cells,
fibroblasts, are green.11 By using the bone marrow from
Coll-GFP mice as the donor to C57BL/6 wild type mice after
sublethal irradiation, only very few fibrocytes with Coll-GFP
expression accumulated in the perivascular area,
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a variety of fibrotic kidney models.11 These fibrocytes really
did not express aSMA or S100A4, but they had CD45, CD14,
major histocompatibility complex class II antigen, and
CD115.
The third possibility is that interstitial myofibroblasts
derive from a precursor cell or multipotent cell within the
kidney. Our previous experiments have demonstrated that
the fibrosis in kidneys after UUO begins from the peri-
vascular area and then extends to the peritubular inter-
stitium. We have demonstrated that circulation-derived
fibrocytes contribute to the fibroblast population very little
(<1%) and there is no EMT in UUO kidneys, therefore, we
hypothesize that myofibroblasts during kidney injury should
derive from endogenous precursor cells. In normal kidneys
of Coll-GFP mice, GFPþ cells are perivascular and inti-
mately associated with endothelial cells (Fig. 1).11,37
Processes or interdigitations can be identified enveloping
capillaries, but the cells do not express aSMA, providing
immunological and morphological evidence that pericytes
are the cells in normal kidney that are generating collagen
1 (a1) transcripts. Although the population of Coll-GFPþ
cells in the kidney includes a small number of perivascular
fibroblasts, microvascular pericytes in the kidney are
defined anatomically as extensively branched cells of
mesenchymal origin that partially surrounded the endo-
thelium of capillaries, whereas perivascular fibroblasts are
spindle-shaped cells of mesenchymal origin surrounded by
collagen matrix and have no close appositions with endo-
thelial cells.11,37 Interestingly and notably, perivascular
aSMAþ vascular smooth muscle cells do not express Coll-
GFP in kidneys, either in normal conditions or after
surgery for UUO or unilateral ischemia reperfusion injury
(IRI).11,37
The morphological diversity of pericytes mirrors diver-
sity also at the molecular level. Several markers have been
used to identify pericytes, including aSMA, desmin, neuron-
glial antigen 2 (NG2) proteoglycan, platelet-derived growth
factor receptor (PDGFR)b, aminopeptidase A and N, regu-
lator of G-protein signaling 5 (RGS5), and the promoter trapFigure 1 Characterization of microvascular pericytes in normal
showed pericytes (Coll-GFP), endothelium (CD31), and capillary ba
processes passing through capillary basement membrane and the
endothelium and pericyte bodies in direct contact. Scale barZ 20
cent protein.transgene XlacZ4.38 However, none of these markers is
absolutely specific for pericytes, and none of the markers
recognizes all pericytes. Their expression is dynamic and
varies between organs and developmental stages. The
heterogeneous morphology and marker expression make
unambiguous identification of pericytes a challenge. State-
of-the-art identification of pericytes, therefore, relies on
combinations of methods, including the use of multiple
markers and high-resolution imaging.
Using Coll-GFP mice we have previously shown that
pericytes are the major sources of myofibroblasts during
kidney injury.11,37,39 Confocal microscopy of normal kidney
cortex shows the direct contact of endothelium and peri-
cyte bodies, and shows pericyte processes passing through
capillary basement membrane. Pericytes are Coll-GFPþ,
PDGFRbþ, PDGFRaþ, CD73þ, Foxd1 progenitor-derived,
aSMA, and CD45 cells.11,28,39,40 After UUO or IRI injury
pericytes lose the intimate connection with endothelium
and increase their population.11,37 aSMA is not detected in
normal kidney pericytes, however, its expression markedly
increases in Coll-GFPþ pericytes, indicating transition to
myofibroblasts after kidney injury (Fig. 2). NG2 proteo-
glycan has been reported to be a marker of pericytes in the
eye and brain, but reports indicate that NG2 is expressed
only by active pericytes.41 Our previous study has shown
that Coll-GFPþ, PDGFRbþ pericytes express NG2 in neonatal
kidney, but they lose expression with maturity.42 Compa-
rable to the increased aSMA expression, pericytes reac-
tivate expression of NG2 soon after UUO injury, indicating
that myofibroblasts are activated pericytes in injured
kidney. In contrast, there is not any one tubular epithelial
cell expressing Coll-GFP in both normal and fibrotic kidneys
(Figs. 1 and 2), further supporting the fact that injured
tubular epithelial cells do not transit to collagen-producing
cells.11,29,37,39
Since our seminal discovery, pericytes of the central
nervous system have been identified as major progenitors
of myofibroblasts in spinal cord wounding, and pericytes
have been shown to be a major source of progenitors
of myofibroblasts in skin, skeletal muscle, lung, andadult kidney. Confocal 4-color image of normal kidney cortex
sement membranes (Laminin a4). Arrowheads showed pericyte
splits in the capillary basement membrane. Arrows showed
mm. T denotes tubules. CollZ collagen; GFPZ green fluores-
Figure 2 Pericyteemyofibroblast transition induced by UUO. Confocal microscopic images showed Coll-GFPþ pericytes (arrow-
heads) in normal control kidney (CON) and Coll-GFPþ myofibroblasts with aSMA expression (arrows) in kidney after UUO. In CON
kidney, aSMA was only expressed in arterial vascular smooth muscle cells denoted by a. T denotes tubules. Scale barZ 20 mm.
CollZ collagen; GFPZ green fluorescent protein; SMAZ smooth muscle actin; UUOZ unilateral ureteral obstruction.
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myofibroblasts in liver disease, have been determined to be
specialized pericytes of the hepatic sinusoid, indicating
that pericytes may represent myofibroblast precursors in
many organs.43e47 Furthermore, many independent studies
support perivascular resident mesenchymal cells, not
injured tubular epithelial cells, as the major source of
myofibroblasts in kidneys.30,42,48,49Crosstalk between pericytes and endothelial
cells
The fact that pericytes are a major source of myofibroblasts
serves to readjust the focus of fibrosis research to the
vasculature. The crosstalk between endothelial cells and
neighboring pericytes soon after kidney injury should be
important for the subsequent renal fibrosis. Pericytes have
been reported to serve as paracrine cells supporting
vascular integrity, and providing important angiogenic
factors including vascular endothelial cell growth factor
(VEGF) and angiopoietin 1.8,50e54 Reciprocally, endothelial
cells are the source of PDGF, TGFb1, and fibroblast growth
factor-2, which all are important growth factors for peri-
cytes.38,55,56 A lack of pericytes has been associated with
aneurysm formation and spontaneous hemorrhage.57,58 And
vice versa, endothelial-cell-derived PDGF signaling is
crucial for pericytes recruitment along developing capil-
laries, as well as vascular stabilization in cancer and
development biology.57,59 Although our previous studies didnot exclude EMT, we did not find evidence of endothelial
cells coexpressing Coll-GFP, suggesting that endothelial
cells in vivo are not a significant source of myofibroblasts.11
However, it is possible for endothelial cells to express
injured signals soon after kidney injury to stimulate
neighboring pericytes. Our recent study has shown that
normal kidney pericytes stabilize capillary tubular networks
with similar capacity to brain pericytes, and in doing so
inhibit metalloproteolytic activity and angiogenic signaling,
but myofibroblasts, derived from pericytes, lose this
vascular stabilizing capacity.4 Microarray analyses have
identified that kidney pericytes rapidly activate expression
of ADAMTS1 (a disintegrin and metalloprotease with
thrombospondin motifs-1) and downregulate its inhibitor,
tissue inhibitor of metalloproteinase 3 (TIMP3) in response
to UUO injury. ADAMTS1 has been reported to degrade
capillary basement membrane proteins and inhibit angio-
genesis and therefore may reasonably facilitate pericyte
detachment.60,61 On the contrary, TIMP3 may silence the
activity of metalloproteinases including ADAM17 and some
matrix metalloproteinases such as matrix
metalloproteinase-14, and has been reported to regulate
vasculogenesis and angiogenesis and to promote tissue
regeneration after injury in the lung.62e64 Similarly to brain
pericytes, kidney pericytes bind to and stabilize capillary
tube networks formed by human umbilical vein endothelial
cells in three-dimensional gels and inhibit metal-
loproteolytic activity and activation at the endothelial-cell-
restricted vascular endothelial cell growth factor receptor
2 (VEGFR2), triggered by serine proteinase kallikrein.4,37 In
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lizing functions despite their derivation from kidney peri-
cytes. These findings suggest that pericyte-derived TIMP3
stabilizes and myofibroblast-derived ADAMTS1 destabilizes
the capillary tubular networks in the kidney. We have
further identified that mice deficient in Timp3 show
a spontaneous microvascular phenotype in the kidney,
resulting from overactivated pericytes with increased
expression of ADAMTS1, and are more susceptible to injury-
stimulated microvascular rarefaction with an exuberant
fibrotic response.4
VEGF-A, the ligand for VEGFR2, is widely expressed in
the normal kidney, including normal kidney pericytes.37 In
rats with UUO injury, VEGF expression has been noted to
increase in the first week and to intensify at the basolateral
aspect of the tubules, accompanied by the increased
proliferation of the adjacent peritubular capillary endo-
thelial cells.65 In addition, we also have demonstrated that
after UUO or IRI injury, there is increased expression of
VEGF-A in macrophages and myofibroblasts. Transcripts for
all three isoforms of VEGF-A are detected in whole kidney.
Injury triggers increased expression of VEGF-A isoforms
VEGF120 and VEGF188 while it triggers decreased expres-
sion of VEGF164 in kidneys after UUO or IRI, suggesting that
these isoforms are being generated in myofibroblasts or
macrophages. Compatible with this hypothesis, VEGF164 is
the predominant isoform in kidney pericytes, but VEGF120
and VEGF188 are expressed at higher levels in kidney
myofibroblasts. Moreover, the timing of switch of VEGF164
expression in favor of VEGF120 and VEGF188 implies an
important role for this switch in disease progression.37
Thus, in the healthy kidney, VEGF164 is the abundant iso-
form that binds to VEGFR2, but during injury, both macro-
phages and myofibroblasts switch to synthesis of VEGF120
and VEGF188; isoforms that are known to lead to dysan-
giogenesis in tumors and developing organs.66,67 Recent
studies in the eye by Dr. Lang at Children’s Hospital in
Cincinnati suggest that pericytes and macrophages may
cooperate to delete endothelial cells during scheduled
developmental vascular regression.50,68 Release of angio-
poietin 2 and Wnt7b from pericytes and macrophages
respectively are necessary for withdrawal of a survival
signal to the endothelial cells and result in cell-cycle-
dependent apoptosis. Notably, we have demonstrated
that UUO kidney macrophages express Wnt7b.69 It will be
interesting to know whether angiopoietin 2 or dysangio-
genic VEGF122 and VEGF188 released by myofibroblasts,
and Wnt7b by macrophages will jointly lead to peritubular
capillary rarefaction and the consequent chronic ischemia,
in addition to losing TIMP3 and increasing ADAMTS1 in
pericyte-derived myofibroblasts during kidney injury.Pericyteemyofibroblast transition in kidney
fibrosis
Pericytes are perivascular cells attached to the abluminal
surface of the capillary endothelium, therefore, we are
intrigued by the role of the endothelium in peri-
cyteemyofibroblast transition during kidney injury. Although
activation of VEGFR signaling may promote adaptive hyper-
trophy of glomeruli and endothelial cell proliferation,subsequent activation of pericytes through endothelial-cell-
derived growth factors and recruited leukocytes are
supposed to promote pericyteemyofibroblast transition. One
elegant study publishedbyHakroush et al used Tet-on tubular
overexpression of VEGF in mice and demonstrated a ubiqui-
tous proliferation of peritubular capillaries and fibroblasts,
followed by excess deposition of extracellular matrix and
therefore fibrosis.70 These studies indicate that crosstalk
between endothelial cells and pericytes is important for the
progressive kidney fibrosis and microvascular rarefaction,
and blockade of either endothelial-cell- or pericyte-
transduced signaling pathways may provide comparable
antifibrotic activity and microvascular preservation. To
target VEGF/VEGFR signaling in fibrotic kidney models, we
haveproven that blockingVEGFR signaling in endothelial cells
may inhibit the activation of PDGFR on pericytes, preserve
microvascular density, and attenuate kidney fibrosis.37
Consequent inhibition of PDGF/PDGFR signaling at pericytes
is one of the possible mechanisms responsible for the bene-
ficial effect of VEGFR targeting.37 Evidence has shown that
VEGF/VEGFR inhibition can indirectly inhibit pericyte
recruitment via primary suppression of endothelial cells and
their PDGF production in the absence of PDGFRb-targeted
inhibition during physiological and tumor angiogenesis.57 In
line with this finding, we have proven that peri-
cyteemyofibroblast transition and renal fibrosis can be
attenuated by targeting pericytes specifically using the
soluble ectodomain of PDGFRb delivered by adenovirus or
anti-PDGFR antibodies.37,39 Hence, early activation of VEGF/
VEGFR signaling at the endotheliummay subsequently induce
pericyteemyofibroblast transition through PDGF/PDGFR
signaling.
In addition to the angiogenic effect, VEGF is known to
increase expression of adhesion molecules in endothelial
cells, including vascular cell adhesion molecule-1, inter-
cellular adhesion molecule-1, and E-selectin, thereby
promoting monocyte migration into injured tissues.71e73
Our previous studies have shown that macrophages, espe-
cially Ly6Clow macrophages (also known as the CX3CR1high
subpopulation), could stimulate pericyte proliferation,
differentiation, and extracellular matrix production in
progressive kidney fibrosis.7e9,27,74
Although the role of PDGFR signaling in inducing aSMA
expression and myofibroblast differentiation of pericytes
in vivo is unequivocal,37,39 in vitro cultured pericytes
increase aSMA expression after TGFb1 stimulation but not
after PDGF treatment, suggesting that PDGF alone might
not be sufficient to induce pericyteemyofibroblast transi-
tion in vivo.39 Our data have shown that targeting either
VEGFR or PDGFR signaling is able to inhibit upregulation of
TGFb1 in injured kidney,37,39 supporting a hypothesis that
TGFb1 may be an important contributing cytokine in
transducing activated VEGFR signaling at the endothelium
and activated PDGFR signaling at pericytes to induce peri-
cyteemyofibroblast transition in vivo.75,76 In previous
investigations of embryonic microvascular development,
endothelial cells have been shown to be a source of both
PDGF and TGFb; cytokines that regulate pericyte attach-
ment, differentiation and angiogenesis.56,58,77 Moreover,
genetic inactivation of either TGFb1 or genes encoding its
receptors in mice leads to vascular defects and embryonic
lethality.77e79 Previous studies have indicated that blocking
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injury and fibrosis,80e83 whereas transgenic overexpression
of TGFb is sufficient to trigger interstitial kidney fibrosis in
the absence of migration of epithelial-derived cells into the
interstitium.29 Therefore, endothelium plays a central role
to activate pericyteemyofibroblast transition by prolifera-
tion and aSMA expression through releasing PDGF and
TGFb1 respectively after injury stimulation (Fig. 3).
Novel therapeutic targets to prevent
pericyteemyofibroblast transition
In addition to the treatments of proven efficacy such as
hypertension control, blockade of the
renineangiotensinealdosterone system, blood sugar
control in diabetes patients, and low protein diet in CKD
patients, several reviews have discussed various novel
interventions targeting renal fibrosis.19,84e88 This present
review focuses on recent advances in targeting peri-
cyteemyofibroblast transition. Pericytes function as a dou-
bleeedged sword. They help maintain normal vascular
structure and angiogenesis in normal development, but
they promote neovascularization in tumor and differentiate
to unwanted myofibroblasts in progressive fibrotic disease if
the injury is persistent or repeated. Blocking peri-
cyteemyofibroblast transition will be a promising therapy
to prevent microvascular rarefaction and renal fibrosis.
Targeting crosstalk between endothelial cells and
pericytes by inhibiting VEGFR signaling
Accompanied with the VEGF dysregulation, our study
confirmed a striking finding that, in the UUO model of
progressive injury, an early angiogenic response is
observed, but followed by peritubular capillary rarefac-
tion, although endothelial cells are still observed to
proliferate at a similar rate.37 Plasma VEGF levels are
higher in CKD and uremic patients than in controlFigure 3 Kidney pericytes and their response to injury. After u
growth factor released from injured tubular epithelial cells, pericyt
PDGF and TGFb. Endothelial cells also express adhesion molecules
tiation into macrophages. Pericytes, in response to PDGF and TGFb
endothelial cells, proliferate, spread and migrate into the intersti
loss, interstitial matrix expansion, and contraction of tissue archi
forming growth factor.individuals.89e91 The negative correlation between plasma
VEGF levels and residual renal function observed in CKD
patients suggests that VEGF may have a negative impact
on CKD progression.92 This speculation may be supported
by recent evidence in humans that increased VEGF
expression significantly correlates with increased macro-
phage infiltration, chronic scarring, and decreased peri-
tubular capillary density.93
We have reported that endothelial activation of VEGFR is
a critical signaling pathway that links endothelial activation
with pericyteemyofibroblast transition.37 In addition,
blocking VEGFR signaling has led to attenuation of inter-
stitial inflammation and downregulation of profibrotic
cytokines including PDGF and TGFb1. Therefore, activation
of endothelial cells at VEGFR is linked to the subsequent
pericyteemyofibroblast transition and macrophage infil-
tration, and persistent dysfunctional activation of VEGFR
signaling will drive microvascular rarefaction, inflammation
and fibrosis.37 Animal studies using neutralizing monoclonal
anti-VEGF antibody or VEGF165 aptamer have shown no
effect on kidney morphology, glomerular cell proliferation
and apoptosis, and proteinuria.94,95 However reversible
renal thrombotic microangiopathy is reported in patients
receiving bevacizumab, a humanized monoclonal antibody
against VEGF.96 This clinical finding is further strengthened
using conditional gene targets to delete VEGF gene from
renal podocytes in mice, which resulted in profound
thrombotic glomerular injury. The effect of VEGFR
blockade in short-term studies in UUO or IRI models by us is
contrary to observations of chronic VEGF-A deletion in
glomerular podocytes.96 The fact that our findings are
reproduced in two models of kidney disease suggests that
the peritubular capillary compartment of the kidney is
different from the glomerular capillary compartment with
respect to VEGF-A signaling. The glomerulus is known as
a vascular bed with high shear stresses and high turnover of
glomerular endothelial cells. It is likely that unlike peri-
tubular capillaries, VEGF-A signaling from podocytes to
endothelial cells is active physiologically and that a chronicnilateral ureteral obstruction injury, vascular endothelial cell
es, and macrophages activates endothelial cells, which produce
to enhance monocyte influx into injured kidney and differen-
, will express a smooth muscle actin, detach themselves from
tium. Persistent injury leads to unstable vasculature, capillary
tecture. PGDFZ platelet-derived growth factor; TGFZ trans-
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talk with endothelium in the glomerulus under physiological
conditions destabilizes the glomerular endothelium. By
contrast, the peritubular capillaries are nonangiogenic in
physiological conditions, and injury-stimulated angiogen-
esis is at first adaptive but subsequently maladaptive.
Moreover, unlike genetic deletion of VEGF-A, soluble
VEGFR2 delivered by adenovirus attenuates VEGF signaling
but does not completely ablate it. Clearly, the distinction
between VEGF/VEGFR signaling in glomeruli and peri-
tubular capillaries requires further study because it may be
that short-term VEGFR blockade is beneficial in acute
injury, whereas chronic blockade is deleterious. Our
previous study has also shown that VEGF dysregulation is
composed of VEGF isoform switch from VEGF164 dominant
to VEGF120 and VEGF188 dominant along with kidney
disease progression induced by either UUO or IRI.37
Although soluble ectodomain of VEGFR2 produced by
adenovirus blocks all VEGF isoforms, it cannot distinguish
which VEGF isoform is detrimental for kidney fibrosis and
microvascular rarefaction.37 Furthermore, VEGF164 may be
important for the normal physiology of glomerular perme-
ability,96,97 therefore blocking VEGF/VEGFR should be
careful. Further studies will be required to understand the
specific role of each VEGF isoform in progressive kidney
fibrosis and microvascular rarefaction.Targeting pericytes by inhibiting PDGFR signaling
PDGFRa and b are expressed exclusively in interstitial
pericytes and myofibroblasts.39 Although VEGFR blockade
attenuates not only VEGFR signaling at endothelial cells but
also PDGFRb signaling at the pericytes, our recent study has
demonstrated that in addition to endothelial cells, PDGF
expression increases markedly in injured tubules (PDGF-B),
and macrophages (PDGF-C) after injury.37 When the acti-
vation of PDGFRa or b is inhibited by receptor-specific
antibody in mice following injury, pericyteemyofibroblast
transition is decreased and injury-stimulated transcripts for
PDGF, TGFb1, and chemokine CCL2 are inhibited. PDGF
ligands are not mitogens for macrophages that do not
express PDGFR. Therefore, inhibition of macrophage infil-
tration is likely secondary to the downregulation of che-
mokines including CCL2. We have further demonstrated
that imatinib, a small molecule inhibitor of PDGFR tyrosine
kinase, may also inhibit pericyte proliferation and kidney
fibrosis in both fibrogenic models of UUO and IRI.39 Although
imatinib may inhibit c-kit receptor kinase, pericytes do not
express c-kit.
Although the role of PDGFR signaling in inducing peri-
cyteemyofibroblast transition in vivo is unequivocal,37,39
in vitro cultured pericytes increase aSMA expression after
TGFb1 stimulation but not after PDGF treatment. TGFb1 is
a downstream of activated VEGFR or PDGFR signaling
during kidney injury,37,39 supporting a hypothesis that
TGFb1 may be an important contributing cytokine in
inducing pericyteemyofibroblast transition in vivo.75,76
Many studies have shown the role of TGFb receptor
(TGFbR) signaling in renal fibrosis.29,80e83,87 Inhibition of
PDGFR and TGFbR signaling provides specific therapeutic
approaches.Targeting macrophage activation
Ly6Clow macrophages are one of the major cell types in the
interstitium producing both PDGF and TGFb1.7e9 We have
recently discovered that a circulating pentameric protein
of the innate immune system, serum amyloid P (SAP) also
known as pentraxin-2, with structural similarities to C-
reactive protein is strongly antifibrotic in kidney disease.9
SAP deposits in injured tissues and opsonizes dead cells
and debris. Once it has opsonized targets, it undergoes
a conformational change converting to a high-affinity ligand
for the activating Fcg receptors (FcgRs). Unlike crosslinking
of FcgRs by immunoglobulin, crosslinking of FcgRs by SAP
does not activate macrophages. Conversely, it inhibits
activation mediated by other stimuli. Part of the mecha-
nism by which SAP inhibits macrophage activation is
through local release of interleukin (IL)-10. IL-10 is an anti-
inflammatory cytokine that is well recognized for inhibiting
inflammation and has direct antifibrotic effects on myofi-
broblasts. By endocytosing and phagocytosing SAP-
opsonized debris, macrophages release IL-10 locally in the
injured kidney, resulting in less activated macrophages that
are unable to activate pericyteemyofibroblast transition
and drive renal fibrosis. Recombinant pentraxin-2 is
currently in phase 2 trials as an antifibrotic therapy for lung
fibrosis, and it clearly may have broad therapeutic
indications.98Conclusions
Normal kidney pericytes stabilize microvasculature,
however pericyte-derived myofibroblasts lose the vascular-
stabilizing ability, lead to peritubular capillary rarefaction
and renal fibrosis. In addition to PDGF produced by injured
tubular epithelial cells, VEGFR signaling at endothelial cells
induced soon after kidney injury stimulates profibrotic
signaling of endothelial cells and recruites macrophages to
activate pericyteemyofibroblast transition. Decreased
activity of PDGFR and TGFbR signaling achieved by selec-
tive blockade of VEGFR at endothelial cells not only
prevents pericyteemyofibroblast transition, but also
attenuates peritubular capillary rarefaction and renal
fibrosis. Selective inhibition of PDGFR signaling or targeting
macrophage activation by pentraxin-2 also provides
novel and safe therapeutic approaches to limit peri-
cyteemyofibroblast transition.Acknowledgments
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